

PRECEPTORSHIP PROGRAMME

Prostate Cancer

Multidisciplinary management,
standards of care, therapeutic
targets and future perspectives

SINGAPORE

15-16 DECEMBER 2016

Co-Chairs Joaquim Bellmunt, USA
Ravindran Kanesvaran, SG

ESMO PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Singapore
15-16 December 2016

CO-CHAIRS: Joaquim Bellmunt, United States of America
Ravindran Kanesvaran, Singapore

SPEAKERS: Arun Azad, Australia
Daniel Y. C. Heng, Canada
Tan Puay Hoon, Singapore
Jin Wei Kwek, Singapore
Lee Lui Shiong, Singapore
Jeffrey Tuan, Singapore

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano - Viganello
Switzerland
Email: courses@esmo.org
www.esmo.org



Thursday, 15 December 2016

08:00-08:15 15'	Opening and welcome	
15'	Welcome from ESMO - objectives and scientific introduction	Joaquim Bellmunt, US
08:15-09:30 75'	SESSION 1 Screening, diagnosis and staging	
20'	PSA screening and diagnosis	Daniel Y. C. Heng, CA
20'	Diagnosis and impact of pathology on prognosis	Tan Puay Hoon, SG
20'	Imaging tests and staging classification	Jin Wei Kwek, SG
15'	Discussion	Faculty

09:30-10:00	Coffee Break	
--------------------	---------------------	--

10:00-11:30 90'	SESSION 2 Localized prostate cancer	
20'	Role of radiotherapy	Jeffrey Tuan, SG
20'	Role of surgery	Lee Lui Shiong, SG
20'	Active surveillance	Joaquim Bellmunt, US
2x15'	2 x Participant clinical case discussion	Faculty

Each 15 min slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion.

11:30-12:30	Lunch	
--------------------	--------------	--

12:30-14:15 105'	SESSION 3 Advanced prostate cancer	
15'	Presentation with lymphadenopathy	Daniel Y. C. Heng, CA
20'	Value and role of PSA as a tumour marker of response/relapse	Daniel Y. C. Heng, CA
10'	Managing urinary obstruction	Lee Lui Shiong, SG
	<u>Debate:</u> This house believes that locally-advanced prostate cancer should be treated with radiotherapy and hormone deprivation	
10'	Argument For	Jeffrey Tuan, SG
10'	Argument Against	Lee Lui Shiong, SG
10'	Discussion	Faculty
2x15'	2 x Participant clinical case discussion	Faculty

Each 15 min slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion.

14:15-14:45	Coffee Break	
--------------------	---------------------	--

14:45-16:30 105'	SESSION 4 Initial systemic therapy	
30'	First-line hormonal therapy for metastatic disease; role and toxicities. Chemotherapy for hormone sensitive disease	Joaquim Bellmunt, US
30'	First and second-line chemotherapy in castration resistance. When to use it.	Ravindran Kanesvaran, SG
3x15'	3 x Participant clinical case discussion	Faculty

Each 15 min slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion.

16:30-18:00 90'	SESSION 5 Castration Resistant Prostate Cancer (CRPC)	
30'	Second-line hormonal therapies	Ravindran Kanesvaran, SG
30'	Isotope therapies and palliative radiotherapy	Jeffrey Tuan, SG
2x15'	2 x Participant clinical case discussion	Faculty

Each 15 min slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion.

19:30	Dinner
--------------	---------------

Friday, 16 December 2016

08:30-10:00 90'	SESSION 6 Immunotherapy and bone-targeting	
20'	Bone targeting (Bisphosphonates and RANK ligands)	Arun Azad, AU
30'	Immunotherapy and other new drug targets	Arun Azad, AU
10'	Discussion: sequencing of treatments	Faculty
2x15'	2 x Participant clinical case discussion	Faculty

Each 15 min slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion.

10:00-10:15 15'	Conclusion and farewell
10:15-10:45	Coffee Break